Application of thistlexanthin in the preparation of antiviral drugs
A technology of thistle and thistle tablets is applied in the application field of thistle in the preparation of antiviral drugs, and can solve the problems of no retrieval, no report on the antiviral effect of thistle, and the like.
Active Publication Date: 2019-07-16
XINJIANG INST OF MATERIA MEDICA
View PDF2 Cites 0 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
However, there are no reports about the antiviral effect of thistlexanthin and its application in the preparation of antiviral drugs at home and abroad, and no relevant literature has been retrieved.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0023] Example 1, the application of this xanthin in the preparation of antiviral drugs.
Embodiment 2
[0024] Embodiment 2, as an optimization of the above-mentioned embodiment, thistlexanthin is extracted from Artemisia marina or plants of the genus Thistle; or, thistlexanthin is obtained by chemical synthesis.
Embodiment 3
[0025] Example 3, as an optimization of the above example, the dosage form of thisxanthin is tablet or capsule.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More PUM
Login to View More Abstract
The invention relates to the technical field of medicines, in particular to application of cirsimaritin in preparing an antiviral drug. The invention for the first time proposes that the cirsimaritin has definite resistance to an influenza virus. The cirsimaritin can significantly inhibit a cytopathic effect caused by the influenza virus infection, and median inhibitory concentrations to an influenza virus A / FortMonmouth / 1 / 1947 and an influenza virus A / jinnan / 15 / 2009 are equivalent to that of an influenza virus Amantadine and an influenza virus Ribavirin; meanwhile, the cirsimaritin can significantly inhibit the expression of influenza virus specific protein M2 protein, and lower an expression level of influenza virus RNA; the intensities of inhibition functions of 40 microgrammes per milliliter of the cirsimaritin on expression of the influenza virus M2 protein and expression of the influenza virus RNA are equivalent to that of 10 micrometers of the Ribavirin, showing that intensity of the anti-influenza virus effect of the cirsimaritin is close to that of antiviral drugs currently commonly used in clinic, and application of the cirsimaritin in preparing anti-influenza drugs has a good prospect.
Description
technical field [0001] The invention relates to the technical field of medicine, and relates to the application of thistlexanthin in the preparation of antiviral drugs. Background technique [0002] The morbidity and mortality of viral infectious diseases are very high, and their spread has caused serious social impact and economic losses. Among the many viruses that have been found in humans, influenza is considered to be the most harmful infectious disease so far. It affects a wide range and causes the largest economic loss among infectious diseases. The influenza pandemic that occurs every year around the world seriously affects people's life and work, and even endangers their lives. In recent years, the continuous emergence of new influenza viruses has made human beings face greater threats. Although vaccination is the most effective way to prevent viral infection, influenza virus is not only highly pathogenic, but also highly variable, and humans cannot obtain long-la...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More Application Information
Patent Timeline
Login to View More Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/352A61P31/12
CPCA61K31/352
Inventor 黄华王林林李玉环王雪颜海燕司丽君高荣梅刘燕章天马雪萍
Owner XINJIANG INST OF MATERIA MEDICA
Features
- R&D
- Intellectual Property
- Life Sciences
- Materials
- Tech Scout
Why Patsnap Eureka
- Unparalleled Data Quality
- Higher Quality Content
- 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com



